Mumbai, June 22, 2007:  Major pharmaceutical companies are predicted to make between 40% and 50% of their revenues by 2010 from in-licensed products implying majority of the licensing deals done at the early stages of development. ChemoCentryx, for example, has signed a drug discovery and development deal with GSK that could be worth $1.5 billion. Accelerated growth rate has been predicted for the biopharmaceutical industry, as the companies annually launch new chemical and innovative entities in order to stay ahead in the competition. In order to become successful player of the life science industry it is crucial to understand the changing dynamics of the industry’s early stage deal-making trends.

Bharat Book Bureau, a leading market information research aggregator, put forth its publication Early Stage and Discovery Deals : Strategy, Structure and Payment Terms 2nd Edition in order to grasp early-stage partnering concept of developing business strategy in this industry.

The pharmaceutical industry has been steadily embracing the idea of the licensing of compounds and drug development programmes  for a number of years now. It may have taken a while to overcome the ‘not invented here’ syndrome, but without a doubt the licensing market is thriving. Licensing is a good way for young, science driven companies – particularly biotechnology firms – to realise some of the value of their work in an industry that has notoriously lengthy development timelines; on the other side of the fence, licensing allows pharmaceutical companies to plug gaps in their pipelines and ensure they have a good portfolio of programmes to help mitigate developmental risk.It is interesting to note that all the top five early stage deals completed in the first  9 months of 2006 were between biotechnology companies and not including big pharma. Indeed, it appears that pharmaceutical deal-making is on the decline, and the biggest rise is for biotech–biotech agreements.

Early-stage partnering being an integral component of  the industry it becomes essential to understand the deal making trends and the basics of deal making structures and the complexities of the payment structure when striking an early stage deal.

This updated edition aims to assist and guide leading professionals dealing in business development through the intricate procedure of early stage deal making, covering payment terms and deal valuations. It also discusses the present partnering model, choosing the right partner, guidelines for structuring an optimal deal, along with with cost analysis between in-licensed projects and in-house pre-clinical projects.

 About Bharat Book Bureau:

Bharat Book Bureau, leading information aggregator based in India, facilitates and supports the business information needs by providing relevant information on pharmaceutical industry published by global agencies on   Pharmaceuticals & Healthcare etc. including country info, technical and management subjects, both in print and electronic format. These include reports, newsletters, country and company profile and online databases.

Kindly visit our website :http://www.bharatbook.com/general/Pharma.asp know more about the publications we handle.

BharatBook.com is an aggregator of global business intelligence representing the most comprehensive collection of published market research available on-demand. Strategy starts with the most relevant, current and credible research available. Strategy starts here.

Copyright © Bharat Book Bureau, 2004."3B" is the Trademark of Bharat Book Bureau.
Phone: (+9122 )27578668 , 27579438 Fax:(+9122 )27579131
Hours: 9:00 am to 8:00 pm IST Monday to Friday & Saturday 9:00 am to 6:00 pm IST
Email: info@bharatbook.com